Key terms
About CYTH
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CYTH news
Mar 19
3:35pm ET
Buy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospects
Jan 23
3:00am ET
Cyclo Therapeutics Regains Compliance with Nasdaq Standards
Dec 29
8:30am ET
One new option listing and one option delisting on December 29th
Dec 28
2:57pm ET
Cyclo Therapeutics closes AMT merger, cash runway extended into 2H
No recent press releases are available for CYTH
CYTH Financials
Key terms
Ad Feedback
CYTH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CYTH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
